Axogen, Inc. (AXGN) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/15/26
Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025GlobeNewsWire • 01/12/26
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)GlobeNewsWire • 12/04/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGNPRNewsWire • 10/18/25
Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGNBusiness Wire • 10/01/25
AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law FirmBusiness Wire • 10/01/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGNGlobeNewsWire • 09/24/25
Does AxoGen (AXGN) Have the Potential to Rally 53.1% as Wall Street Analysts Expect?Zacks Investment Research • 08/28/25
Wall Street Analysts Predict a 76.37% Upside in AxoGen (AXGN): Here's What You Should KnowZacks Investment Research • 08/12/25
Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth ConferenceGlobeNewsWire • 07/29/25